復星醫藥(02196.HK)與關連方共向私募基金公司天津星耀減資500萬人幣
復星醫藥(02196.HK)(600196.SH)公布,控股子公司復健基金、公司、天津復曜與公司的控股股東
復星高科技,擬對共同投資的私募基金公司天津星耀進行同比例減資500萬元人民幣(下同)。
減資後天津星耀財產份額由1,000萬元減少至500萬元,其中復健基金管理公司、公司、天津復曜、復星高科技認繳/實繳出資額分別減少5萬元、222萬元、125萬元、148萬元。
本次減資完成後,各合夥人所持天津星耀的份額比例不變。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.